Higuchi, Tomoaki
Takagi, Kae
Tochimoto, Akiko
Ichimura, Yuki
Hirose, Hikaru
Sawada, Tatsuo
Shibata, Noriyuki
Harigai, Masayoshi
Kawaguchi, Yasushi
Funding for this research was provided by:
JSPS KAKENHI (JP 20K17456)
the Ministry of Health, Labour, and Welfare (JPMH20FC1044)
Article History
Received: 21 February 2023
Accepted: 4 November 2023
First Online: 8 November 2023
Competing interests
: MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. In addition, MH received speaker fees from AbbVie Japan GK, AstraZeneca K.K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd., and UCB Japan Co. Ltd. MH is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. The Division of Multidisciplinary Management of Rheumatic Diseases is an endowment department supported by an unrestricted grant from Ayumi Pharmaceutical Corp., Asahi Kasei Corp., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and AbbVie Japan GK.